Skip to main content
. 2023 Aug 23;24(17):13077. doi: 10.3390/ijms241713077

Figure 4.

Figure 4

Summary of treatment for case 2. MET alterations in red. LAC: lung adenocarcinoma; PS: performance status; PY: pack-years; SCC: squamous cell carcinoma; cfDNA: cell-free DNA; Osi: Osimertinib; and Crizo: Crizotinib.